Drug regimen puts Erie-area woman's pancreatic cancer 'in hibernation'

Twelve months later, Miller is healthy and preparing to host her family's holiday gathering. A regimen of biological drugs ...
Managed Healthcare Executive

UC Davis develops new drug for bladder cancer patients

A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...
The Manila Times

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...
Live Science on MSN

It matters what time of day you get cancer treatment, study suggests

Giving immunotherapy earlier in the day can significantly extend patients' survival, compared to giving treatment later in ...
Hub

Patient sees dramatic drop in HIV-infected immune cells after cancer treatment

In a person living with HIV, proviruses—strands of HIV DNA—are typically integrated into the T cell genome and become a ...
pharmaphorum

J&J's subcutaneous Rybrevant cleared by FDA

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
The White House

INCREASING MEDICAL MARIJUANA AND CANNABIDIOL RESEARCH

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose and ...
pharmaphorum

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
Fierce Pharma

J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.
The Manila Times

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute ...
CURE

Updated Treatment Options Improve Advanced HR+ Breast Cancer Outcomes

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
Agence France-Presse

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...